These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7647063)

  • 1. Chemotherapy changes the DNA ploidy in ovarian cancer.
    Venesmaa P; Paavonen J; Forss M; Ylikorkala O
    Br J Obstet Gynaecol; 1995 Jul; 102(7):568-9. PubMed ID: 7647063
    [No Abstract]   [Full Text] [Related]  

  • 2. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
    Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [DNA ploidy in epithelial ovarian cancer--an independent prognostic factor].
    Tropé CG; Abeler V; Baekelandt M; Kaern J
    Tidsskr Nor Laegeforen; 2000 Jan; 120(1):43-9. PubMed ID: 10815478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor?
    Tropé C; Kaern J
    Gynecol Oncol; 1994 Apr; 53(1):1-4. PubMed ID: 8175006
    [No Abstract]   [Full Text] [Related]  

  • 5. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
    Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
    Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical value of DNA ploidy in ovarian cancer].
    Obrebowska A; Spaczyński M
    Ginekol Pol; 1997 Oct; 68(10):478-82. PubMed ID: 9780508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA ploidy as a prognostic factor in patients with ovarian carcinoma.
    Pietrzak K; Olszewski W
    Pol J Pathol; 1998; 49(3):141-4. PubMed ID: 9810171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of preoperative chemotherapy on nuclear DNA content in osteosarcoma.
    Baldini N; Gebhardt MC; Springfield DS; Litwak GJ; Mankin HJ
    Chir Organi Mov; 1990; 75(1 Suppl):22-4. PubMed ID: 2249539
    [No Abstract]   [Full Text] [Related]  

  • 9. BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
    Aghmesheh M; Saxena A; Niknam F
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):135-41. PubMed ID: 25428229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of new ploidy-related parameters for the diagnosis of ovarian tumours.
    Korabiowska M; Brinck U; Skubis J; Sattler B; Fischer G
    Anticancer Res; 2004; 24(6):4191-4. PubMed ID: 15736472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
    Meyer JS; Gersell DJ; Yim S
    Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric analysis of nuclear DNA content in patients with recurrent epithelial ovarian cancer.
    Hamaguchi K; Nishimura H; Tateno N; Yakushiji M; Yokoyama MM
    Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2836-42. PubMed ID: 2074393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics and ovarian cancer.
    Nephew KP; Balch C; Zhang S; Huang TH
    Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
    [No Abstract]   [Full Text] [Related]  

  • 14. Ovarian carcinoma heterogeneity as demonstrated by DNA ploidy.
    Zangwill BC; Balsara G; Dunton C; Varello M; Rebane BA; Hernandez E; Atkinson BF
    Cancer; 1993 Apr; 71(7):2261-7. PubMed ID: 8453547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study.
    Kaern J; Tropé CG; Kristensen GB; Tveit KM; Pettersen EO
    Am J Obstet Gynecol; 1994 Feb; 170(2):479-87. PubMed ID: 8116701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
    Lage JM; Weinberg DS; Huettner PC; Mark SD
    Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DNA examinations in gynecological cancer and breast cancer].
    Tropé C; Kaern J; Pettersen EO; Iversen OE
    Tidsskr Nor Laegeforen; 1991 May; 111(13):1638-42. PubMed ID: 2063365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable ploidy of ovarian clear cell carcinomas. Implications for adequacy of tissue sampling.
    Listinsky CM; Bonfiglio TA; Leary J
    Anal Quant Cytol Histol; 1988 Feb; 10(1):21-7. PubMed ID: 3355646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
    Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.